InterCure Ltd (NASDAQ:NASDAQ:INCR) Q2 2022 Earnings Conference Call August 16, 2022, 08:30 ET Company Participants Adam Haliva - Communications Officer Alexander Rabinovitch - CEO &.
InterCure Ltd s (INCR) CEO Alex Rabinovitch on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Subversive Acquisition LP Closes Transaction With InterCure, Israel’s Leading and Fastest-Growing Cannabis Company
InterCure is the Most Well-Capitalized Cannabis Company in Israel and is Positioned to Consolidate the Israeli Market and Further Expand Across Europe
Combined Company led by Chairman and Former Prime Minister of Israel Ehud Barak and CEO Alex Rabinovitch
InterCure has Doubled Revenues Sequentially in Four of the Last Five Quarters; Growth Plans Include Tripling Retail Footprint by 2022
Common Shares of InterCure now Trade on the TSX Under the Symbol “INCR.U” and the TASE Under the Symbol “INCR”
Listing of InterCure’s Shares on NASDAQ Expected in Q2 2021 and Will Trade Under the Symbol “INCR”
Subversive Acquisition LP Provides Update on Qualifying Transaction With InterCure, Israel’s Leading and Fastest-Growing Cannabis Company
Subversive Acquisition LP Has Met All Conditions of Closing and Expects to Close on or Before Friday April 23, 2021
SPAC Restricted Voting Units Currently Trade on the TSX Under the Symbol “SVX.U” and the OTCQX Under the Symbol “SBVRF”
On Closing Common Shares of InterCure will Trade on the TSX Under the Symbol “INCR.U” and the TASE Under the Symbol “INCR”
Listing of InterCure’s Shares on NASDAQ Expected in Q2 2021 and Trade Under the Symbol “INCR”
NEW YORK and TORONTO and HERZLIYA, Israel, April 21, 2021 (GLOBE NEWSWIRE) Subversive Acquisition LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) a special purpose acquisition company (SPAC), today announced it has met all conditions of closing, with the exception for the closing condition that will be met upon InterCure’s shares trading on the TSX, for its qualify